SYMPOSIA

More documents

Recommendations

Info

Turkish Association for Psychopharmacology 4th International Congress on Psychopharmacology “Innovations and continuity in psychiatry & psychopharmacology: better care for better health” November 23-27, 2011 Antalya, Turkey www.psychopharmacology2011.org POSTER PRESENTATIONS
Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org Poster Presentations [PP-001] Ref. No: 133 Visual hallucinations induced by bupropion: A case report Sevda Korkmaz 1 , Murat Kuloglu 2 , Sadullah Saglam 3 , Murad Atmaca 2 1 Department of Psychiatry, 3 Department of Neurology, Psychiatric Hospital 2 Department of Psychiatry Firat University School of Medicine, Elazig-Turkey E-mail: skorkmaz23@hotmail.com Bupropion is an antidepressant, which inhibits reuptake of norepinephrine and dopamine. It is a relatively reliable antidepressant in terms of side effects and also is used in the treatment of nicotine deprivation (1, 2). Most frequent side effects are insomnia, dry mouth, and headache (3). Here we present a case who developed visual hallucinations during bupropion treatment. Case: F.Y: A 51 year old woman was admitted to the outpatient clinic with complaints of hump, horror, and seeing spider images. Visual hallucinations, anxiety, irritability, insomnia, and anhedonia were noted on psychiatric examination. Except for the visual hallucinations, there was no other perception abnormality nor other psychotic symptoms. History: she reported to a psychiatrist with complaints of joylessness, weakness, fatigue, and anhedonia. She was diagnosed with major depressive disorder and subsequently was put on bupropion 150mg/day. After a week, the dosage of bupropion was increased to 300mg/day. On the first day of the bupropion dose increase to 300 mg/day, spider images developed in both of her eyes and in the following days these images increasingly continued. The images lasted for days and scared the patient, ruined her sleep pattern, and increased her anxiety. The patient saw an ophthalmologist with these complaints and at the medical examination there was no evidence of an organic or pathological disorder. Her blood pressure was under control with treatment. The patient had been treated with escitalopram and duloxetine 6 years ago with a diagnosis of depressive disorder, but the patient specified that she had not had any visual complaints. There were not any relevant symptoms at that time and patient was not describing any clear stress factors. The family history was unremarkable. The patient did not have such complaints as dizziness, tinnitus, or paraesthesia and there was not any pathological finding at the neurological examination. Also there were no abnormal findings in the blood tests, urinalysis, and MR imaging. The Beck depression, Beck anxiety, and SCL-90 scales showed high levels of anxiety and moderate depression. After the assessment of all these data, suspicion was focused on the bupropion as the main cause of the spider images (visual hallucinations). The patient did not accept hospitalization, thus she was followed up periodically. First the dosage of bupropion was decreased to 150 mg and bupropion treatment was stopped completely in a few days. Alprazolam 0.5 mg/day treatment was started to decrease the patient’s anxiety. Paroxetine 10 mg/ day was started and increased to 30 mg/day in two weeks. Following the discontinuation of the bupropion, the visual hallucinations disappeared in a few days. The patient came for controls monthly and at the end of the 6th month the symptoms of depression and anxiety had decreased considerably. Comment: Bupropion has become a popular antidepressant in the treatment of depressive disorders in Turkey and is preferred frequently because of its relatively low incidence of side effects. Nevertheless every kind of side effects including psychotic symptoms that appear during treatment should be assessed carefully. Key words: Bupropion, hallucination, antidepressant References: 1. Ascher JA, Cle JO, Colin JN, et al. Bupropion: A review of its mechanism of antideressant activity. J Clin Psychiatry 1995;56:395-401. 2. Englisch S, Inta D, Eer A, Zink M (2010) Bupropion for depression in schizophrenia. Clin Neuropharmacol; 33(5): 257-259. 3. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained release bupropion and placebo. N Engl J Med 1997;337:1195-1202. Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S121 [PP-002] Ref. No: 139 Clinical features of patients with panic disorder in outpatient clinics of a psychiatric training and research hospital Ramazan Konkan 1 , Erkan Aydın 1 , Oya Güçlü 1 , Ömer Şenormancı 1 , Mehmet Z. Sungur 2 1 MD, Psychiatrist in Deparment of Psychiatry in Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul Turkey 2 MD, Proffessor in Deparment of Psychiatry, Marmara University School of Medicine, Istanbul Turkey E-mail: ramazankonkan@gmail.com Objective: Panic disorder is a disorder characterized by recurrent unexpected panic attacks where the patient may exhibit avoidance S121
Page 1 and 2:
With Contributions of
Page 3 and 4:
Turkish Association for Psychopharm
Page 5 and 6:
Nihat ALPAY Rüstem AŞKIN Ömer AY
Page 7 and 8:
NOVEMBER 23, 2011 WEDNESDAY TIME HA
Page 9 and 10:
NOVEMBER 25, 2011 FRIDAY AT A GLANC
Page 11 and 12:
13.30 15.00-16.00 17.30-19.30 17.30
Page 13 and 14:
09.00-10.30 PS-04: Adult attention
Page 15 and 16:
20.30-22.30 KC-01: Biostatistics -
Page 17 and 18:
09.00-10.30 PS-09: From preclinical
Page 19 and 20:
09.00-10.30 PS-10: Will glutamaterg
Page 21 and 22:
09.00-10.30 JS-05: Indian Psychiatr
Page 23 and 24:
NOVEMBER 26, 2011 SATURDAY 09.00-10
Page 25 and 26:
NOVEMBER 27, 2011 SUNDAY 09.00-10.3
Page 27 and 28:
Author(s) Abstracts of the Invited
Page 29 and 30:
Author(s) Abstracts of the Invited
Page 31 and 32:
Author(s) Poster Presentation 16 A.
Page 33 and 34:
Author(s) Poster Presentation 60 Ba
Page 35:
Author(s) Poster Presentation 108 O
Page 38 and 39:
Abstracts of the Invited Speakers O
Page 40 and 41:
Abstracts of the Invited Speakers p
Page 42 and 43:
Abstracts of the Invited Speakers D
Page 44 and 45:
Abstracts of the Invited Speakers R
Page 46 and 47:
Abstracts of the Invited Speakers [
Page 48 and 49:
Abstracts of the Invited Speakers H
Page 50 and 51:
Abstracts of the Invited Speakers m
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Abstracts of the Invited Speakers d
Page 58 and 59:
Abstracts of the Invited Speakers e
Page 60 and 61:
Abstracts of the Invited Speakers d
Page 62 and 63:
Abstracts of the Invited Speakers S
Page 64 and 65:
Abstracts of the Invited Speakers o
Page 66 and 67:
Abstracts of the Invited Speakers N
Page 68 and 69:
Abstracts of the Invited Speakers I
Page 70 and 71:
Abstracts of the Invited Speakers E
Page 72 and 73:
Abstracts of the Invited Speakers G
Page 74 and 75: Abstracts of the Invited Speakers T
Page 76 and 77: Abstracts of the Invited Speakers A
Page 78 and 79: Abstracts of the Invited Speakers l
Page 80 and 81: Abstracts of the Invited Speakers E
Page 82 and 83: Abstracts of the Invited Speakers R
Page 84 and 85: Abstracts of the Invited Speakers i
Page 86 and 87: Abstracts of the Invited Speakers
Page 90 and 91: Abstracts of the Invited Speakers A
Page 92 and 93: Abstracts of the Invited Speakers P
Page 94 and 95: Abstracts of the Invited Speakers [
Page 98 and 99: Abstracts of the Invited Speakers O
Page 100 and 101: Abstracts of the Invited Speakers T
Page 102 and 103: Abstracts of the Invited Speakers e
Page 104 and 105: Abstracts of the Invited Speakers o
Page 106 and 107: Abstracts of the Invited Speakers S
Page 108 and 109: Abstracts of the Invited Speakers C
Page 110 and 111: Abstracts of the Invited Speakers [
Page 112 and 113: Abstracts of Oral Presentations [SO
Page 114 and 115: Abstracts of Oral Presentations Mat
Page 116 and 117: Abstracts of Oral Presentations wit
Page 118 and 119: Abstracts of Oral Presentations pat
Page 120 and 121: Abstracts of Oral Presentations ade
Page 122 and 123: Abstracts of Oral Presentations eff
Page 126 and 127: Poster Presentations behavior by ex
Page 128 and 129: Poster Presentations [PP-005] Ref.
Page 130 and 131: Poster Presentations fulfilling the
Page 134 and 135: Poster Presentations eating disorde
Page 136 and 137: Poster Presentations Conclusion: Th
Page 138 and 139: Poster Presentations had no treatme
Page 140 and 141: Poster Presentations 80 mg/day (dos
Page 154 and 155: Poster Presentations Based on the r
Page 160 and 161: Poster Presentations study, the Cro
Page 168 and 169: Poster Presentations motivations fo
Page 172 and 173: Poster Presentations 4. Şükrü Ka
Page 174 and 175:
Poster Presentations [PP-081] Ref.
Page 176 and 177:
Poster Presentations References: 1.
Page 178 and 179:
Poster Presentations when meeting a
Page 180 and 181:
Poster Presentations MADRS and HAM-
Page 182 and 183:
Poster Presentations in terms of co
Page 184 and 185:
Poster Presentations schizophrenia
Page 186 and 187:
Poster Presentations ascending dopa
Page 188 and 189:
Poster Presentations study. The inc
Page 190 and 191:
Poster Presentations and Spaniards.
Page 192 and 193:
Poster Presentations patients, and
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Poster Presentations 22.7%, bipolar
Page 202 and 203:
Poster Presentations future, we exp
Page 204 and 205:
Poster Presentations of action, ami
Page 206 and 207:
Poster Presentations pharmacologica
Page 208 and 209:
(±)-3-4-methylenedioxymethamphetam
Page 210 and 211:
Panic symptoms S122 Paroxetine S156
Page 212 and 213:
Etli T. S162 Evren C. S80, S154, S1
show all

SYMPOSIA

Create successful ePaper yourself

Delete template?

Save as template?